Retrospective Study on Effectiveness and Safety of First–line Chemotherapy in Metastatic Colorectal Cancer Patients

Abstract

Objectives: To evaluate the efficacy and safety of first–line chemotherapy treatment in patient with metastatic colorectal cancer (mCRC) and relative dose intensity per plan of treatment (RDI/plan of treatment), and to determine factors affecting progressive free survival (PFS) and overall survival (OS). Methods: The research was a retrospective study that reviewed medical records and electronic databases during Jan 1, 2012 and Dec 31, 2018. The subjects were those aged ≥ 18 years who diagnosed with mCRC and receiving chemotherapy and/or targeted therapy as a first–line treatment. The primary outcomes were OS, PFS, response rate and adverse effects from chemotherapy. The secondary outcome was RDI/plan of treatment. Results: Among 114 patients, 15 received chemotherapy less than 4 cycles. As a result, the effectiveness was not assessed in this group of patients. Therefore, there were 99 subjects with the assessment of effectiveness. The median OS was 22.0 months (95%CI 19.21 – 24.79), and median PFS was 8.33 months (95%CI 7.53 – 9.13). The response rate at partial response was found in 44.74% of subjects. All patients were analyzed for safety. Any grades of severity of hematologic toxicities were anemia (35.96%), neutropenia (34.21%) and thrombocytopenia (30.43%). Most common non-hematologic toxicities were peripheral neuropathy (48.2%), oral mucositis (47.4%), and fatigue (35.1%), etc. Mean RDI /plan of treatment was 84.55%. No factors associated with OS and PFS were identified. Conclusions: Patients with mCRC receiving chemotherapy as a first–line treatment had a median OS of 22.0 months, and median PFS of 8.33 months. The most common hematologic toxicities were anemia, thrombocytopenia and neutropenia. Common non–hematologic toxicities included peripheral neuropathy and oral mucositis. Mean RDI/plan of treatment was 84.55%.